Aripiprazole Lauroxil Long-Acting Injectable: The Latest Addition to Second-Generation Long-Acting AgentsAuthor(s): Arpit Aggarwal, Ganesh Gopalakrishna, John Lauriello
Antipsychotics have long been the mainstay for the treatment of schizophrenia and other psychotic disorders. Longacting injectables (LAI) of antipsychotics—provided once every two weeks to once every three months—promise to reduce the incidence of nonadherence. ARISTADA™ (aripiprazole lauroxil; ALLAI) extended-release injectable suspension was approved by the U.S. Food and Drug Administration in October 2015 for the treatment of schizophrenia, and is the newest entrant in the LAI market. ALLAI is available as a single-use, pre-filled syringe, can be started in three different dosages, and also has the option of every six-week dosing. Treatment with oral aripiprazole is recommended for the first twenty-one days after the first ALLAI injection, which is a potential disadvantage. Adverse effects include sensitivity to extrapyramidal symptoms, especially akathisia, which is well documented in other aripiprazole preparations. There is no available data comparing ALLAI to other antipsychotics, and more head-to-head trials comparing different LAI formulations are needed. Based on the available data, ALLAI is an effective and safe option for treatment of schizophrenia. Further studies and post-marketing data will provide better understanding of this formulation.